Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHR vs SAX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AHR Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

AHR Overall Winner 6-Pillar Tally: AHR 5 – 0 SAX (1 Tie) Matrix Metrics: AHR 8 – 2 SAX

As of Nov 20, 2026, American Healthcare REIT, Inc. (AHR) is the stronger overall head-to-head candidate over SAX (SAX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AHR carries a Unified Composite Score of 44.7/100 (HOLD) at $57.54 (63.9x Forward P/E, 6.8% operating margin), whereas SAX carries 52.0/100 (HOLD) at $24.43 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While SAX currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. AHR 44.7/100 HOLD), AHR captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (6.8% vs. N/A operating margin) and revenue trajectory (+29.4% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHR vs SAX
AHR NYSE Head-to-Head Winner
American Healthcare REIT, Inc.
Real Estate Investment Trusts
$57.54
-0.12% 1D
Market Cap $13.4B
TTM Revenue $2.67B
Forward P/E 63.9x
Beta / 30D Vol 0.02β · 28% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 33.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 59
RSI-14: 58.7 · SMA20: $56.27 · SMA50: $53.77
SAX US Equity
SAX
Institutional Equity
$24.43
+0.37% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.10β · 8% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (AHR 5 – 0 SAX)

Columns: Metric · AHR · SAX
1. Valuation Multiples AHR
Forward P/E 63.9x N/M
Trailing P/E 117.6x N/M
PEG Ratio N/M N/M
EV / Revenue 5.0x N/M
2. Growth & Scale AHR
Revenue Growth (YoY) +29.4% N/A
Earnings Growth (YoY) -57.6% N/A
TTM Revenue (USD) $2.67B N/A
Market Cap $13.4B N/A
3. Profitability & Quality AHR
Gross Margin 20.3% N/A
Operating Margin 6.8% N/A
Net Profit Margin 3.6% N/A
Return on Equity (ROE) 2.3% N/A
4. Balance Sheet & Cash Flow AHR
Cash Generation (TTM) $497M EBITDA N/A
Cash Flow Margin 18.6% EBITDA Mgn N/A
Net Cash / Leverage $23.91 Book/Sh · 2.3% ROE N/A ROE
Dividend Yield 1.71% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 31.1% (27th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat AHR
OpEx & R&D Intensity 13.5% of Rev ($361M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role REIT - Healthcare Facilities Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHR (8) vs SAX (2)
Institutional Metric AHR SAX Criterion Row Edge
Market Capitalization
Scale
$13.4B N/A Larger Scale AHR
Trailing P/E Ratio
Valuation
117.6x N/M Lower Multiple AHR
Forward P/E Ratio
Valuation
63.9x N/M Lower Multiple AHR
Revenue Growth (YoY)
Growth
+29.4% N/A Higher Growth AHR
Operating Margin (TTM)
Profitability
6.8% N/A Higher Margin AHR
Net Profit Margin
Profitability
3.6% N/A Higher Margin AHR
Return on Equity (ROE)
Capital Efficiency
2.3% N/A Higher ROE AHR
52-Week Range Position
Momentum
86% ($45–$60) 25% ($24–$26) Stronger Trend AHR
Beta / 30D Volatility
Risk Regime
0.02β · 28% Vol 0.10β · 8% Vol Lower Realized Risk SAX
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 52.0 / 100 (HOLD) Higher Composite SAX
Trailing 12M Revenue (USD)
Operating Scale
$2.67B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
20.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$497M EBITDA ($23.91 Book/Sh · 2.3% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHR +10.03 pp
AHR: +7.75% · SAX: -2.28%
3M Horizon AHR +2.77 pp
AHR: +1.88% · SAX: -0.89%
6M Horizon AHR +2.77 pp
AHR: +1.88% · SAX: -0.89%
1Y Horizon AHR +2.77 pp
AHR: +1.88% · SAX: -0.89%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AHR vs SAX. Trailing 12-month operating profitability (AHR 6.8% vs SAX N/A) and valuation multiples (AHR 63.9x vs SAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AHR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.67B
Gross Margin20.3%
Op. Margin6.8%
ROE / Fwd P/E2.3% · 63.9x
SAX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 31.1%
IV Percentile 27th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AHR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SAX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHR Moat Profile Cyclical / Execution-Driven Positioning
REIT - Healthcare Facilities Operator
Competes within the REIT - Healthcare Facilities value chain with $13.4B market capitalization and 6.8% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($361M)
90D Engineering Disclosures 0 Published
SAX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AHR vs SAX Key Questions & Quantitative Answers

As of Nov 20, 2026, American Healthcare REIT, Inc. (AHR) is the stronger overall head-to-head candidate over SAX (SAX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AHR carries a Unified Composite Score of 44.7/100 (HOLD) at $57.54 (63.9x Forward P/E, 6.8% operating margin), whereas SAX carries 52.0/100 (HOLD) at $24.43 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While SAX currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. AHR 44.7/100 HOLD), AHR captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (6.8% vs. N/A operating margin) and revenue trajectory (+29.4% vs. N/A YoY).

AHR leads the Growth & Scale pillar: AHR posts +29.4% YoY revenue growth and -57.6% YoY earnings growth on $2.67B TTM revenue (20.3% gross margin, 6.8% operating margin), compared with SAX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, AHR generates $2.67B in USD-normalized revenue versus N/A for SAX. In operating R&D and SG&A reinvestment, AHR deploys 13.5% of Rev ($361M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SAX.

AHR screens cheaper on headline valuation multiples. AHR trades at 63.9x Forward P/E, 117.6x Trailing P/E, N/M PEG, and 5.0x EV/Revenue (18.6% EBITDA margin), whereas SAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHR (2.3% ROE) versus SAX (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, AHR carries 31.1% implied volatility (27th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.02β · 28% Vol realized risk). By comparison, SAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.10β · 8% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.